A recombinant fowlpox virus (rFPV/E2) expressing the E2 protein of bovine viral diarrhea virus (BVDV) was constructed and characterized. Mice were immunized with recombinant virus and both humoral and cellular immune responses were studied. rFPV/E2 induced BVDV-specific antibodies which were detected by ELISA. In addition, mouse sera were shown to neutralize BVDV. A cytokine ELISA assay revealed that mice vaccinated with rFPV/E2 induced 7-fold more interferon-Q than parental fowlpox virus. z
Introduction
Bovine viral diarrhea virus (BVDV) is classi¢ed in the pestivirus genus of the Flaviviridae family [1] and is a ubiquitous pathogen of cattle causing signi¢cant economic losses. Vaccines currently available have not been successful in eliminating this pathogen.
BVDV contains a single-stranded positive-sense RNA molecule of approximately 12.5 kb which has a single open reading frame (ORF) encoding a number of structural and non-structural polypeptides that are co-translationally and post-translationally cleaved from polyprotein precursors [2] . Three structural glycoproteins E rns (gp48), E1 (gp25) and E2 (gp53) are encoded in the ¢rst third of the ORF. The E2 (gp53) protein is a major viral glycoprotein which is highly antigenic and elicits the production of neutralizing antibodies in the host after infection or vaccination with live or killed vaccines. The majority of BVDV neutralizing antibodies are directed against the E2 protein [3, 4] . Two di¡erent forms of E2 protein, E2 (53 kDa) and E2p7 (60 kDa), can be found in infected cells depending on the di¡erent cleavage patterns in their C-terminal tail [5] . The role of the E2 protein of BVDV in cellular immunity is not very well known. However, in the case of hog cholera virus, another pestivirus, the E1 protein (the E2 homologue in BVDV) was shown not to be a major T-cell antigen [6] .
Fowlpox virus (FPV) is a member of the avipox genus of the Orthopoxvirus family. In contrast to vaccinia virus, which has a very broad vertebrate host range, other members of the family such as the avipox genus are naturally restricted for productive replication to avian species [7] . Nevertheless, avipox virus vectors, like FPV and canarypox virus, engineered to express extrinsic antigens can elicit protective immune responses to viral pathogens in non-avian species [8^10]. FPV-based recombinant vaccines possess several advantages as vaccine vectors. The virus is safe since it was used previously in protection against the poultry disease. The virus is also stable and inexpensive to produce. It is capable of initiating an abortive infection in non-avian cells and expresses antigens on the infected cell surface. Consequently it can induce both cellular and humoral immune responses [8^10] .
In this paper we used recombinant FPV to study the role of the E2 protein of BVDV in the induction of both humoral and cellular immune responses.
Materials and methods

Cells and viruses
Primary chicken embryo ¢broblast (CEF) cell cultures were prepared from 9^11-day-old speci¢c pathogen-free embryos essentially by the method of Solomon [11] . CEF cells were grown in DMEM/F12 medium supplemented with 4% fetal bovine serum (FBS) and antibiotics. The vaccine strain of FPV, Poxine (Solvay Animal Health, Inc., Mendota Heights, MN ,USA) was used as the parental virus to construct a recombinant virus (rFPV/E2). The parental FPV (pFPV) and rFPV/E2 were grown and their infectivity titrated in CEF cells (expressed as TCID SH ml 3I and pfu ml 3I ). The NADL strain (BVDV type I) and Madin-Darby kidney (MDBK) cells were obtained from the American Type Culture Collection (Rockville, MD, USA). The 125 strain (BVDV type II) was obtained from USDA (Ames, IA, USA).
Construction of plasmid vectors
Molecular cloning procedures were essentially as described by Maniatis et al. [12] . The intermediate plasmid pFPVtkgpt was constructed by cloning the 1.1-kb PCR product of the tk gene [13] in EcoRI/ HindIII-digested pUC18 (Gibco BRL) and the subsequent insertion of a synthetic bi-directional promoter element with early/late and late functions [14] , £anked by a synthetic multiple cloning site (MCS) in the blunt-ended XbaI site of the tk gene (Fig. 1) . The Escherichia coli gpt gene £anked by the P7.5 promoter of the vaccinia virus from pTKgptF1s [15] was cloned as a BamHI/CalI fragment in pBCKS (Stratagene) and removed as a BamHI/ XhoI fragment for subsequent cloning into pFPVtkBi. Also, the GFP gene from pS65T [16] was digested with BamHI/XbaI and, following ¢lling in, was inserted in the SmaI site of pFPVtkBi. The vector, pFPVtkBigptGFP, contains a unique BamHI site for the cloning of the target gene. The construction of pcDNA/gp53 which contains the E2 (gp53) fragment of strain NADL of BVDV (nucleotides 2414^3725) has been described previously [17] . Plasmid pcDNA/gp53 BglII was derived from pcDNA/ gp53 by adding two annealed oligonucleotides 5P-CTAGCAGATCTG-3P and 5P-GTCTAGACGA-TC-3P to generate a BglII site at the XbaI site of the MCS. The resulting plasmid was digested with Bam-HI/BglII and the E2 fragment was cloned into the BamHI site of pFPVtkBigptGFP. The ¢nal plasmid containing the E2 gene of BVDV was designated pFPVtkBigptGFP/E2 (Fig. 1). 
Generation and puri¢cation of rFPV/E2
Procedures for transfection of FPV-infected cells with the transfer vector DNA and the generation of rFPV have been described previously [18] . The progeny virus was passaged three times on CEF cells under two selective conditions. Brie£y, 5 h prior to infection of the 60-mm dish of CEF cells with 102 0% of progeny virus (in 0.5^1 ml of medium), the medium (DMEM with 2% v/v FBS) was replaced with medium containing 20 Wg ml 3I of 5-bromo-2P-deoxyuridine (BUdR) or MXHAT (10 Wg ml 3I mycophenolic acid, 250 Wg ml 3I xanthine, 13.6 Wg ml 3I hypoxanthine, 2 Wg ml 3I aminopterin and 8 Wg ml 3I thymidine). After adsorption, the selective media were replaced and the conditions maintained until 4^5 days post infection (p.i.). The parental virus failed to grow in medium containing BUdR or MXHAT, while rFPV/E2 was enriched under these conditions. The progeny virus was subjected to three rounds of plaque puri¢cation on CEF cells. At 5 days p.i. plaques were picked and placed into 300 Wl of medium (EMEM with 2% calf serum). Recombinant viruses were identi¢ed by dot-blot hybridization of infected CEF cells. The methods for alkaline lysis of cells and membrane preparation have been described previously [19] . The probe was labelled with the digoxigenin (DIG) (Boehringer Mannheim) and the detection kit from the same company was used according to the manufacturer's instructions.
Characterization of rFPV/E2
One-step growth curves to compare the intracellular and extracellular viruses for both pFPV and rFPV/E2 were done as described previously [20] . The viral DNAs of rFPV/E2 and pFPV were analyzed by Southern blotting as described by Parks et al. [21] .
Radioimmunoprecipitation analysis
The protocols for metabolic labelling and immunoprecipitation of antigen from CEF cells infected with rFPV/E2 or pFPV and MDBK cells infected with NADL have been previously described [4, 21] . Monoclonal antibody (mAb) D89 to the BVDV/E2 protein, kindly provided by Dr. H.C. Minocha (Kansas State University, Manhattan, KS, USA), was used for immunoprecipitation of E2 protein.
Immunization of mice
Four groups of 10 inbred BALB/c mice were inoculated in the footpad with 50^100 Wl of a range of dilutions from 4U10
S to 4U10 U pfu of rFPV/E2 or 4U10 U pfu of pFPV. Booster immunizations were given at 3 and 6 weeks after the priming injection. Bleeding was performed from orbital puncture at 0, 3, 6, 9, and 12 weeks post injection (p.i.) (Table 1) .
Enzyme-linked immunosorbent assay (ELISA)
The MDBK cells infected with the NADL strain of BVDV were re-suspended in carbonate bicarbonate bu¡er (NaHCO Q 35 mM, Na P CO Q 15 mM, NaN Q 0.02%, pH 9.6). After three freeze-thaw cycles, the supernatant was treated with N-octylglucoside (2% ¢nal concentration), and the plates were coated by diluted antigens in carbonate bicarbonate bu¡er at a concentration of 1 Wg in 50 Wl. After blocking with 5% skim milk (1 h at 37³C), diluted mouse sera (1:160) were added to the wells in duplicate, and the plates were incubated for 30 min at 37³C. HRP-goat anti-mouse IgG (1:8000, Bio-Rad) was used as the second antibody (30 min at 37³C) and tetramethylbenzidine as the substrate (10 min at room temperature). The positive cut-o¡ OD was considered as the mean OD RSH values for each sample greater than the mean OD RSH value obtained from mice in group I plus two times the standard deviation (ODW0.18).
Neutralization test (NT)
After complementation inactivation of mouse sera at 56³C for 30 min, 50 Wl of virus solution containing 100 TCID SH of BVDV (NADL strain) was added to 50 Wl of serial twofold serum dilutions (starting at 1:10) and the plates were incubated for 1 h at 37³C. Then, 100 Wl of medium containing 3U10 R MDBK cells was added to each well. Each serum dilution was tested in quadruplicate. Plates were incubated at 37³C in 5% CO P for 5 days. The highest serum dilution that inhibited the cytopathic e¡ect in at least 50% of the cultures was considered the virus neutralization titer.
Proliferation response of murine mononuclear cells (MNC)
At 15 weeks p.i. splenocytes of ¢ve mice from groups I and IV were pooled and suspended at a concentration of 3U10
T MNC ml 3I in RPMI 1640 supplemented with 10% FBS, 2 mM sodium pyru- 
Cytokine detection assay
1.5U10
T murine MNC were stimulated with BVDV (NADL and 125 strains) at a ¢nal dilution of 1/10 or mock-stimulated. Three days later 100 Wl of supernatants in duplicate were used in the cytokine ELISA assay (PharMingen) for detection of interleukin (IL)-2, IL-4 and interferon-Q (IFN-Q) according to the manufacturer's instructions.
Results and discussion
Generation of rFPV/E2
The transfer vector, pFPVtkBigptGFP/E2, was constructed by interrupting the FPV tk gene by inserting three elements into the tk gene of FPV. (1) The E. coli gpt gene was cloned under the control of the P7.5 promoter, thus allowing the selection of recombinant viruses in the presence of medium containing MXHAT. (2) The GFP gene was cloned under the control of the late function of the bi-directional promoter of FPV. (3) The expression of the BVDV E2 was controlled by the early/late function of the bi-directional promoter. Because the expression of the tk gene was interrupted, the rFPV/E2 was tk 3 , and therefore only rFPV/E2 could be ampli¢ed in the presence of BUdR. The transfer vector pFPVtkBigptGFP/E2 was used to transfect CEF cells previously infected with pFPV. After three rounds of ampli¢cation in the presence of BUdR and/or MXHAT, the putative recombinant viruses were plaque puri¢ed four times in the absence of selection medium and identi¢ed by dot blot hybridization. Both selection media were e¡ective for enrichment of rFPV. However, better results were ob- Fig. 1 . Construction of the transfer vector pFPVtkBigptGFP/E2 from pFPVtkBi. The pFPVtkBi was constructed by insertion of the gene in pUC18 and a synthetic bi-directional promoter (Bi.pro.) in the XbaI site of the tk gene as described in Section 2. Then, (1) the gpt gene (BamHI/XhoI) from pBCKSgpt was inserted into BamHI/XhoI of pFPVtkBi, (2) the GFP gene (BamHI/XhoI-end ¢lled) from pS65T was inserted into the SmaI site, and (3) the E2 gene of BVDV (BamHI/BglII) from pcDNAgp53 BglII was inserted into the BamHI site to generate the transfer vector pFPVtkBigptGFP/E2. served in the presence of BUdR (data not shown). During BUdR selection, only recombinant viruses with double cross-over will be tk 3 and can grow. In the presence of MXHAT, both single and double cross-over recombinant viruses can express the gpt gene and can grow in the selection medium. The rFPV/E2 with a single cross-over is unstable and undergoes subsequent rounds of recombination, leading to the formation of both stable recombinant (double cross-over) and parental viruses.
Screening on the basis of GFP expression was ef¢cacious when cells in 96-well plates were infected by eluted plaques during the plaque puri¢cation step. Supernatants of the wells that were positive within 2^3 days p.i. by GFP were used for subsequent plaque puri¢cation, without waiting for dot blot results. Expression of GFP was also used as an indicator of the presence of rFPV/E2. A decrease in the number of GFP cells in subsequent passages was the ¢rst sign of the presence of pFPV in the viral population. Finally, £uorescent activated cell sorter (FACS) or other appropriate equipment for the isolation of GFP cells could be used to enrich for rFPV/E2 by isolation of GFP cells. However, enrichment for rFPV/E2 by using the BUdR or MXHAT selection media considerably increased the percentage of GFP cells and thus facilitated the task.
Characterization of rFPV/E2
The presence of one copy of the E2 gene in the 5.5-kb HindIII-digested fragment of rFPV/E2 was con¢rmed by Southern blot (data not shown). Titration of both the virus in culture medium and the cellassociated viruses revealed that rFPV/E2 produced 2.4-fold fewer infectious extracellular and 1.8-fold fewer infectious intracellular viruses than pFPV at 72 h p.i. This di¡erence between the two viruses was apparent as early as 18 h p.i. and remained roughly constant throughout the course of infection (Fig. 2) . This di¡erence could be due to the interruption of the tk gene in rFPV/E2. Letellier [22, 23] has also demonstrated that tk recombinant pigeonpox virus has a growth advantage over tk 3 recombinant virus.
Expression of the E2 protein by rFPV/E2
The D89 mAb was used to precipitate the E2 protein (53 kDa) in BVDV-infected MDBK cells (Fig. 3,  lane 2) . A protein of about 60 kDa was also coprecipitated. This protein could be the E2p7 protein which was reported previously [5] . However, in CEF cells infected with rFPV/E2, the size of the E2p7 protein was slightly lower (57 kDa) as our construct lacked 22 amino acids at the C-terminal end of the E2p7 protein (Fig. 3, lane 4) . No speci¢c proteins Table 1 Serum Bleeding was performed by orbital plexus puncture at 0, 3, 6, 9 and 12 weeks p.i. The mouse sera were tested in ELISA and NT for detection of BVDV-speci¢c antibody and neutralization antibody against E2 protein of BVDV, respectively. In both tests, the numbers of positive mice/ numbers of total mice in each experiment are shown. Dose expressed as pfu per mouse.
In ELISA the mouse sera with OD s 0.18 at dilution 1/160 were considered positive. The di¡erence between OD in groups II, III and IV and that in group I was signi¢cant in Pearson's t-test (two-tailed) *P 6 0.05, **P 6 0.005, ***P 6 0.0005. In NT the mouse sera neutralizing BVDV/NADL strain at a minimal dilution of 1/10 were considered positive. The average of neutralizing antibodies for positive samples þ S.D. is shown in parentheses. The mouse sera with titer 6 10 were considered negative. d No positive samples were detected before 6 weeks p.i.
were observed when lysates of pFPV-infected cells were immunoprecipitated with the D89 mAb (Fig.  3, lane 3) .
Humoral immune response to rFPV/E2
Mouse sera were assayed for BVDV-speci¢c antibodies in an indirect ELISA. Table 1 shows that the humoral immune response to BVDV E2 protein was dose-dependent. When mice were injected with 4U10
T and 4U10 U pfu of rFPV/E2 (group III and IV), all the mice seroconverted at 6 weeks p.i. But only 20% of mouse sera immunized with 4U10 S pfu of rFPV/E2 (group II) were seropositive by ELISA at the same time. Neutralization antibodies at a minimal titer of 10 were also detected in 20% and 60% of mice in groups II and III, respectively, at 9 weeks p.i. (Table 1 ). 60% of mice in group IV possessed antibodies that neutralized the BVDV/NADL strain after 6 weeks p.i. Both the number of mice positive for the presence of neutralization antibodies against BVDV and also the titer of neutralizing antibodies were dose-dependent. The immune response increased from two mice with titers of 10 þ 0 in group II to eight mice with titers of 21 þ 12 in group IV at 12 weeks p.i. (Table 1) . To demonstrate that the route of injection had no e¡ect on neutralization titers, a separate group of mice were injected by the intramuscular route with 4U10 U pfu of rFPV/ E2, following the same protocol used for group IV. No di¡erences were observed in the neutralizing titer (data not shown).
Cellular immune responses
ELISA assays for IFN-Q revealed the production of 2200 þ 160 pg ml 3I of IFN-Q by the murine MNC immunized with rFPV/E2 (group IV) compared with 284 þ 23 pg ml 3I by the murine MNC immunized with pFPV (group I), after stimulation with the BVDV/NADL strain. No IFN-Q was detected after stimulation with the BVDV/125 strain. This signi¢-cant increase in IFN-Q concentration (7-fold) in the supernatant of murine MNC immunized with rFPV/ E2 compared to the group immunized with pFPV could be caused by the activation of speci¢c Th1 cells. No increases were observed in the production of IL-2 and IL-4. It is more di¤cult to understand why no proliferative responses were observed after stimulation of murine MNC with the BVDV/ NADL or 125 strains, particularly when considering the strong non-speci¢c proliferation response to pFPV. The stimulation index for mice immunized with pFPV was 2.8^13 (depending on the dilution of BVDV/NADL), compared with 2.6^4.5 for rFPV/E2. This non-speci¢c proliferation may have masked speci¢c T-cell responses to BVDV by rFPV/E2. Another possible explanation for the absence of speci¢c lymphoproliferation in response to BVDV stimulation could be the e¡ect of the high levels of IFN-Q and/or prostaglandins produced via activated macrophages [24^26] . As part of a separate study, we have investigated the e¡ect of indomethacin, an inhibitor of prostaglandin E2, on the restoration of proliferative responses. Using a recombinant adenovirus expressing the nucleocapsid of BVDV, we found that the proliferation response to the recombinant adenovirus was detectable only in the presence of indomethacin (unpublished data). This result derives from the potent ability of prostaglandins to inhibit T-cell mitogenesis and IL-2 production [27] .
In conclusion, mice immunized with the recombinant FPV, rFPV/E2, induced a neutralizing humoral immune response. In addition, the BVDV E2 protein induced high levels of IFN-Q which suggests the activation of Th1 cells. This study demonstrated the e¤cacy of rFPV/E2 as a BVDV recombinant immunogen, and encourages further study to evaluate the use of rFPV/E2 as a vaccine in cattle, the natural host for BVDV.
